SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 50,000 |
| Revenue | 54.3B USD (2023) |
AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 13 |
| Sector (Life Science) | 8 of 13 |
| Type (Add-on Acquisition) | 7 of 12 |
| State (Massachusetts) | 1 of 4 |
| Country (United States) | 6 of 11 |
| Year (2023) | 1 of 2 |
| Size (of disclosed) | 3 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-10-20 |
DJS Antibodies
Oxford, United Kingdom DJS Antibodies is a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors. DJS Antibodies is based in Oxford, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-12-06 |
Cerevel
Cambridge, Massachusetts, United States Cerevel is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia, and addiction. Cerevel was formed in 2018 and headquartered in Cambridge, Massachusetts. |
Buy | $8.7B |
